Zacks article cautions buying Keryx because it's gone up so much this year citing manufacturing issues. Seriously?? Old news. What a joke.
The competitors got this iron overload warning on the Auryxia label, but according to the phase3 clinicals there was no iron overload, except for people also taking IV iron. This was a warning that shoul;d have said if you are taking Auryxia you should stop IV iron. Dr. Davis had said in her research iron overload did not exist in her studies of the phase 3 trials. I am sure this hurt Auryxia sales more than management did.
A tale of two stocks! In Oct. of 2014 POS KERX was $14 to $15 a share. In that same time frame NVDA was was even lower $13 to $14 a share. Which stock would you rather have now. This is why you leave a loser like JERX and buy another stock. I wish I got NVDA at those prices but I did buy it under $100 and it is on its way to $200 while POS KERX is still 2x under its 2014 mark.Stop dreaming and move on
I have tried multiple times to post a link from an interesting patient comment that I found on Stocktwits, and Yahoo will not let it post. Check out Stocktwits for KERX, and look for a link starting patient(dot)info.
ADVANCES IN THE TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
by Pablo E. Pergola, MD PhD Director of Research Renal Associates PA San Antonio, Texas and Clinical Associate Professor of Medicine Division of Nephrology UT Health San Antonio
NICE PRESENTION with a very good overview about treatment options, including Auryxia of course
There is no Iron overdose reported by people who take Auryxia yet. This review analyzes which people have Iron overdose with Auryxia. It is created by eHealthMe based on reports from FDA, and is updated regularly.
Lets see a run over $8 this week
AURYXIA IRON OVERLOAD WARNING LABEL
Here are the official entries of adverse effects in conjunction with iron overload reported to the FDA and documentated in the database EHEALTHME
There is one word for such a "high" quantity of iron overload reports: UNREMARKABLE
Will you have Iron overdose with Auryxia - from FDA reports - eHealthMe
$KERX ims 947 4 day week . From StockTwits
OPTION. i brlieve they are going to try and get a close below $7.00 so that most calls expire worthless. especially sine the put call ratio is big time tilted toward calls.
This should be a $14.00 stock now and after the PDUFA we will be around $ 20.00
Is NephrologyCat still around? Can someone break down the indication differences, if there are any, b/n Auryxia and Vadadustat? Curious why Butler would be allowed to serve on the board so long if $AKBA and $KERX are legitimate direct competitors? Doesn't really make sense.
Longs...just keep buying more shares when the idiocy hands of the short conspiracy lays bs like today. Tick tock shorts...where are you going to find 18M available shares before November 1st (if you have that long). 90%+ held by insiders and institutions doesn't leave much on the table for you.
WOW !! 0.50 cents down on no news. This stock is so easy to be manipulated.
Old School guy
A lot going on this week. Probably mostly technical but investors might be worried about how scripts will be after 1/4 of the US was under water last week. Any sideways movement will be short lived. Also, Seth Klarman announced he is returning cash to investors, perhaps selling some positions to raise cash??? We are 6 weeks from a major potential approval and 8 months of sales under our belt and the stock is at $6.80. 14 months ago in July we were 17 months from possible approval and only a couple of months of sales in the bag and the stock was 50c higher at $7.25. Thanks again for this great opportunity. Bought 10k more today at 7.05 and 6.92.
Less than 60 days to the PDUFA, and there will be NO extension and e will not be disappointed. The market for Auryxia will triple overnight and the sales will begin immediately. MD's are embracing this drug with their DDCKD patients due to it's much better tolerability profile as well as it's other advantages for patients. The acceptance of the drug by MD's will be just as strong for their NDDCKD patients and the benefits will beat anything else on the market---either prescription or OTC. Auryxia already has a "warning" associated with it which I believe insults the intelligence of every nephrologist who prescribes it, and it will have no impact on prescribing for their NDDCKD patients. This the lull before the runup really begins and one of the last chances before approval to get in at this level. While the stock price may drop SLIGHTLY from where it is now, I think it has a solid shot at $10 before approval and when it is officially approved for expanded use it will be a completely different situation from the last approval and the stock will JUMP-----bigly!
Seems like Call 5 and Put 13 made all the money....find out who bought those and you will find the crooks that manipulated the stock price
Keryx Biopharmaceuticals Inc. KERX: This New York-based biopharmaceutical company focuses on treating patients suffering from renal disease. The company’s shares have risen 20.1% so far this year. However, it currently carries a Zacks Rank #4. Further, over the last 60 days, the loss per share estimates widened by 92.5% for 2017. Though the company’s label expansion efforts for its only marketed drug, Auryxia bode well for growth, supply interruption of Auryxia, may hurt sales in future quarter.